Kevin Kraus's most recent trade in 8X8 Inc. was a trade of 1,000 Common Stock done at an average price of $1.8 . Disclosure was reported to the exchange on May 15, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.81 per share. | 15 May 2025 | 1,000 | 441,767 (0%) | 0% | 1.8 | 1,810 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.67 per share. | 15 Apr 2025 | 1,000 | 442,767 (0%) | 0% | 1.7 | 1,670 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.14 per share. | 15 Mar 2025 | 12,250 | 444,767 (0%) | 0% | 2.1 | 26,215 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.19 per share. | 15 Mar 2025 | 1,000 | 443,767 (0%) | 0% | 2.2 | 2,188 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.34 per share. | 18 Feb 2025 | 1,000 | 457,017 (0%) | 0% | 3.3 | 3,340 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.12 per share. | 15 Feb 2025 | 624 | 458,017 (0%) | 0% | 3.1 | 1,947 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.60 per share. | 15 Jan 2025 | 1,000 | 458,641 (0%) | 0% | 2.6 | 2,600 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.63 per share. | 13 Dec 2024 | 11,070 | 460,641 (0%) | 0% | 2.6 | 29,059 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.65 per share. | 13 Dec 2024 | 1,000 | 459,641 (0%) | 0% | 2.6 | 2,649 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.89 per share. | 15 Nov 2024 | 1,000 | 472,275 (0%) | 0% | 2.9 | 2,890 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.81 per share. | 15 Nov 2024 | 564 | 471,711 (0%) | 0% | 2.8 | 1,585 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.10 per share. | 15 Oct 2024 | 1,000 | 473,275 (0%) | 0% | 2.1 | 2,100 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2024 | 200,000 | 483,270 (0%) | 0% | 0 | Common Stock | |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.83 per share. | 15 Sep 2024 | 7,995 | 475,275 (0%) | 0% | 1.8 | 14,661 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.85 per share. | 15 Sep 2024 | 1,000 | 474,275 (0%) | 0% | 1.9 | 1,850 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.70 per share. | 15 Aug 2024 | 1,000 | 283,676 (0%) | 0% | 1.7 | 1,704 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.71 per share. | 15 Aug 2024 | 406 | 283,270 (0%) | 0% | 1.7 | 694 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.33 per share. | 15 Jul 2024 | 1,000 | 284,676 (0%) | 0% | 2.3 | 2,330 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.93 per share. | 17 Jun 2024 | 11,681 | 285,676 (0%) | 0% | 1.9 | 22,507 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.90 per share. | 17 Jun 2024 | 9,391 | 297,357 (0%) | 0% | 1.9 | 17,852 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.93 per share. | 17 Jun 2024 | 9,364 | 306,748 (0%) | 0% | 1.9 | 18,035 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.03 per share. | 17 Jun 2024 | 1,000 | 316,112 (0%) | 0% | 2.0 | 2,030 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.86 per share. | 15 May 2024 | 1,000 | 317,512 (0%) | 0% | 2.9 | 2,860 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.70 per share. | 15 May 2024 | 400 | 317,112 (0%) | 0% | 2.7 | 1,078 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.33 per share. | 15 Apr 2024 | 1,000 | 318,512 (0%) | 0% | 2.3 | 2,330 | Common Stock |
AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 30,000 | 31,914 | - | 0 | Common Stock | |
AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 15 Mar 2024 | 30,000 | 31,914 | - | 0 | Common Stock | ||
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.67 per share. | 15 Mar 2024 | 1,433 | 319,512 (0%) | 0% | 2.7 | 3,819 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.67 per share. | 15 Mar 2024 | 1,000 | 321,307 (0%) | 0% | 2.7 | 2,672 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.67 per share. | 15 Mar 2024 | 362 | 320,945 (0%) | 0% | 2.7 | 965 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.69 per share. | 16 Feb 2024 | 487 | 322,307 (0%) | 0% | 2.7 | 1,312 | Common Stock |
8X8 Inc. | Kraus Kevin | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.75 per share. | 15 Feb 2024 | 1,000 | 322,794 (0%) | 0% | 2.8 | 2,750 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.50 per share. | 16 Jan 2024 | 1,000 | 323,794 (0%) | 0% | 3.5 | 3,500 | Common Stock |
AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 09 Jan 2024 | 7,417 | 1,914 | - | 20.1 | 149,367 | Common Stock | |
AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 09 Jan 2024 | 5,000 | 9,331 | - | 6.6 | 33,000 | Common Stock | |
AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 09 Jan 2024 | 5,000 | 26,832 | - | - | Stock Option (right to buy) | ||
AN2 Therapeutics Inc | Krause Kevin | Chief Strategy Officer | 09 Jan 2024 | 2,417 | 49,868 | - | - | Stock Option (right to buy) | ||
AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 09 Jan 2024 | 2,417 | 4,331 | - | 0.4 | 1,015 | Common Stock | |
AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 02 Jan 2024 | 2,583 | 4,497 | - | 0.4 | 1,085 | Common Stock | |
AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 02 Jan 2024 | 2,583 | 1,914 | - | 20.1 | 51,967 | Common Stock | |
AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 02 Jan 2024 | 2,583 | 52,285 | - | - | Stock Option (right to buy) | ||
8X8 Inc. | Kraus Kevin | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.53 per share. | 18 Dec 2023 | 4,062 | 324,794 (0%) | 0% | 3.5 | 14,355 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.53 per share. | 18 Dec 2023 | 1,209 | 328,856 (0%) | 0% | 3.5 | 4,272 | Common Stock |
8X8 Inc. | Kraus Kevin | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.53 per share. | 18 Dec 2023 | 306 | 330,065 (0%) | 0% | 3.5 | 1,081 | Common Stock |
8X8 Inc. | Kraus Kevin | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.65 per share. | 12 Dec 2023 | 1,000 | 330,371 (0%) | 0% | 3.7 | 3,650 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 16 Aug 2023 | 404 | 337,498 (0%) | 0% | 3.5 | 1,401 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.49 per share. | 17 Jul 2023 | 478 | 337,902 (0%) | 0% | 4.5 | 2,145 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 221,100 | 348,017 (0%) | 0% | 0 | Common Stock | |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.85 per share. | 15 Jun 2023 | 5,063 | 342,633 (0%) | 0% | 3.9 | 19,502 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.85 per share. | 15 Jun 2023 | 4,253 | 338,380 (0%) | 0% | 3.9 | 16,381 | Common Stock |
8X8 Inc. | Kevin Kraus | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.85 per share. | 15 Jun 2023 | 321 | 347,696 (0%) | 0% | 3.9 | 1,236 | Common Stock |
8X8 Inc. | Kevin Kraus | Interim Chief Financial Off. | Sale of securities on an exchange or to another person at price $ 3.16 per share. | 16 May 2023 | 402 | 126,917 (0%) | 0% | 3.2 | 1,271 | Common Stock |
8X8 Inc. | Kevin Kraus | Interim Chief Financial Off. | Sale of securities on an exchange or to another person at price $ 3.74 per share. | 17 Apr 2023 | 480 | 127,319 (0%) | 0% | 3.7 | 1,797 | Common Stock |
8X8 Inc. | Kevin Kraus | Interim Chief Financial Off. | Sale of securities on an exchange or to another person at price $ 4.83 per share. | 16 Mar 2023 | 6,317 | 127,799 (0%) | 0% | 4.8 | 30,528 | Common Stock |
8X8 Inc. | Kevin Kraus | Interim Chief Financial Off. | Sale of securities on an exchange or to another person at price $ 6.06 per share. | 16 Feb 2023 | 1,618 | 134,116 (0%) | 0% | 6.1 | 9,809 | Common Stock |
AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 15 Feb 2023 | 62,200 | 62,200 | - | - | Stock Option (right to buy) | ||
8X8 Inc. | Kevin Kraus | Interim Chief Financial Off. | Sale of securities on an exchange or to another person at price $ 4.58 per share. | 17 Jan 2023 | 1,824 | 133,708 (0%) | 0% | 4.6 | 8,356 | Common Stock |
8X8 Inc. | Kevin Kraus | Interim Chief Financial Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2022 | 45,977 | 135,836 (0%) | 0% | 0 | Common Stock | |
8X8 Inc. | Kevin Kraus | Interim Chief Financial Off. | Sale of securities on an exchange or to another person at price $ 4.73 per share. | 15 Dec 2022 | 304 | 135,532 (0%) | 0% | 4.7 | 1,438 | Common Stock |
AN2 Therapeutics Inc | Kevin Krause | Chief Strategy Officer | 12 May 2022 | 66,000 | 66,000 | - | - | Stock Option (right to buy) |